“2019 Corporate Restructuring Transactions” means, collectively, the following transactions: # the creation of [[Lead Borrower:Organization]] Medical Technologies Corp., a Delaware corporation, which shall be a wholly-owned Subsidiary of the Lead Borrower and shall serve as a holding company, # the transfer of 100% of the shares of WOM World of Medicine USA Inc., a Florida corporation, to [[Lead Borrower:Organization]] Medical Technologies Corp. on or around December 31, 2019 and # the transfer of 100% of the shares of Laser Quantum Inc., a Delaware corporation, to the Lead Borrower on or around December 31, 2019 and the subsequent liquidation of Laser Quantum Inc. on or around December 31, 2019.

“2019 Corporate Restructuring Transactions” means, collectively, the following transactions: # the creation of [[Lead Borrower:Organization]] Medical Technologies Corp., a Delaware corporation, which shall be a wholly-owned Subsidiary of the Lead Borrower and shall serve as a holding company, # the transfer of 100% of the shares of WOM World of Medicine USA Inc., a Florida corporation, to [[Lead Borrower:Organization]] Medical Technologies Corp. on or around December 31, 2019 and # the transfer of 100% of the shares of Laser Quantum Inc., a Delaware corporation, to the Lead Borrower on or around December 31, 2019 and the subsequent liquidation of Laser Quantum Inc. on or around December 31, 2019.

“2019 Corporate Restructuring Transactions” means, collectively, the following transactions: # the creation of [[Lead Borrower:Organization]] Medical Technologies Corp., a Delaware corporation, which shall be a wholly-owned Subsidiary of the Lead Borrower and shall serve as a holding company, # the transfer of 100% of the shares of WOM World of Medicine USA Inc., a Florida corporation, to [[Lead Borrower:Organization]] Medical Technologies Corp. on or around December 31, 2019 and # the transfer of 100% of the shares of Laser Quantum Inc., a Delaware corporation, to the Lead Borrower on or around December 31, 2019 and the subsequent liquidation of Laser Quantum Inc. on or around December 31, 2019.

Rest of World. Subject to Sections 3.1 and 3.2 above, in all markets other than ​, ​:

“Fee Letter” means that certain Second Amended and Restated Fee Letter, dated March 17, 2017, among the Borrower, Bank of America, N.A., Merrill Lynch, Pierce, Fenner & Smith, Incorporated, Barclays Bank PLC, Credit Suisse Securities (USA) LLC, Credit Suisse AG, Citigroup Global Markets Inc., Macquarie Capital (USA) Inc., Macquarie Capital Funding LLC, Morgan Stanley Senior Funding, Inc., Deutsche Bank AG New York Branch, Deutsche Bank AG Cayman Islands Branch, Deutsche Bank Securities Inc., Goldman Sachs Bank USA, Royal Bank of Canada, Blackstone Holdings Finance Co. L.L.C., Canadian Imperial Bank of Commerce, New York Branch and CIBC World Markets Corp., as the same may be amended, supplemented or otherwise modified from time to time.

“Fee Letter” means that certain Second Amended and Restated Fee Letter, dated March 17, 2017, among the Borrower, Bank of America, N.A., Merrill Lynch, Pierce, Fenner & Smith, Incorporated, Barclays Bank PLC, Credit Suisse Securities (USA) LLC, Credit Suisse AG, Citigroup Global Markets Inc., Macquarie Capital (USA) Inc., Macquarie Capital Funding LLC, Morgan Stanley Senior Funding, Inc., Deutsche Bank AG New York Branch, Deutsche Bank AG Cayman Islands Branch, Deutsche Bank Securities Inc., Goldman Sachs Bank USA, Royal Bank of Canada, Blackstone Holdings Finance Co. L.L.C., Canadian Imperial Bank of Commerce, New York Branch and CIBC World Markets Corp., as the same may be amended, supplemented or otherwise modified from time to time.

On behalf of Foundation Medicine, Inc. (“Foundation Medicine” or “the Company”), I am very pleased to offer you the position of Chief Business Officer and Head, Biopharma.

“Amendment No. 1 Arrangers” means Merrill Lynch, Pierce, Fenner & Smith Incorporated (or any other registered broker-dealer wholly-owned by Bank of America Corporation to which all or substantially all of Bank of America Corporation’s or any of its subsidiaries’ investment banking, commercial lending services or related businesses may be transferred following the date of this Agreement), Barclays Bank PLC, Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc., Macquarie Capital (USA) Inc., Morgan Stanley Senior Funding, Inc., Deutsche Bank Securities Inc., Goldman Sachs Bank USA, RBC Capital Markets, LLC and CIBC World Markets Corp., each in its capacity as joint lead arranger and joint bookrunner of Amendment No. 1, and Blackstone Holdings Finance Co. L.L.C., in its capacity as co-manager of Amendment No. 1.

“Amendment No. 1 Arrangers” means Merrill Lynch, Pierce, Fenner & Smith Incorporated (or any other registered broker-dealer wholly-owned by Bank of America Corporation to which all or substantially all of Bank of America Corporation’s or any of its subsidiaries’ investment banking, commercial lending services or related businesses may be transferred following the date of this Agreement), Barclays Bank PLC, Credit Suisse Securities (USA) LLC, Citigroup Global Markets Inc., Macquarie Capital (USA) Inc., Morgan Stanley Senior Funding, Inc., Deutsche Bank Securities Inc., Goldman Sachs Bank USA, RBC Capital Markets, LLC and CIBC World Markets Corp., each in its capacity as joint lead arranger and joint bookrunner of Amendment No. 1, and Blackstone Holdings Finance Co. L.L.C., in its capacity as co-manager of Amendment No. 1.

“Amendment No. 4 Arrangers” means BofA Securities, Inc., Barclays Bank PLC, CIBC World Markets Corp., Citigroup Global Markets Inc., Credit Suisse Loan Funding LLC, Deutsche Bank Securities Inc., Goldman Sachs Bank USA, Morgan Stanley Senior Funding, Inc. and RBC Capital Markets, LLC, each in its capacity as joint lead arranger and joint bookrunner of Amendment No. 4, and Blackstone Advisory Partners L.P., in its capacity as co-manager of Amendment No. 4.